News
ORKA
90.60
+4.58%
3.97
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
Benzinga · 5d ago
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)
TipRanks · 5d ago
Oruka Therapeutics SVP Finance Arjun Agarwal disposes of 1,587 common shares worth $127,454.28
PUBT · 5d ago
Monday's ETF Movers: XBI, RONB
NASDAQ · 6d ago
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
Benzinga · 6d ago
Monday Sector Leaders: Biotechnology, Shipping Stocks
NASDAQ · 6d ago
BTIG says others may be interested in Apogee Therapeutics
TipRanks · 6d ago
Weekly Report: what happened at ORKA last week (0615-0619)?
Weekly Report · 6d ago
Oruka Therapeutics Insiders Quietly Cash In With Fresh Stock Sales
TipRanks · 06/16 02:05
Oruka Therapeutics CMO Joana Goncalves disposes of USD 552,429 common shares
PUBT · 06/15 22:55
Weekly Report: what happened at ORKA last week (0608-0612)?
Weekly Report · 06/15 09:01
Oruka Therapeutics director Carl Dambkowski disposes of $2.46 million in common shares
PUBT · 06/12 20:37
Weekly Report: what happened at ORKA last week (0601-0605)?
Weekly Report · 06/08 09:01
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 06/05 03:30
Oruka Therapeutics Shareholders Back Governance and Executive Pay
TipRanks · 06/04 22:03
Oruka Therapeutics shareholders elect Klein, Martin as Class II directors at annual meeting
PUBT · 06/04 20:19
Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged
TipRanks · 06/03 11:25
Piper Sandler Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 06/02 11:55
UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 06/02 11:47
More
Webull provides a variety of real-time ORKA stock news. You can receive the latest news about Oruka Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).